Navigation Links
MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute
Date:4/11/2011

SAN DIEGO, April 11, 2011 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received the Phase 2 portion of the Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI) under the agency's Streamlined Non-competing Award Procedures (SNAP). The initial year 1 grant of $150,000 was awarded on August 1, 2010 and supported the manufacture and testing of the company's sarcoma vaccine currently in clinical testing. The follow-on grant is intended to help support the Phase II clinical trial of the company's vaccine to prevent recurrent sarcoma.  The year 2 award is for $974,000 and the year 3 award is for an additional $878,000.  

"We are very gratified that the NCI has made this follow-on award to MabVax.  These grants will significantly help offset the costs of the Phase II trial such as investigational site and certain patient care expenses," said David Hansen, CEO of MabVax.  He added that "the trial now has 10 active sites enrolling patients and we have made good progress toward reaching our enrollment goals."

The Phase II clinical trial will enroll a total of 134 metastatic sarcoma patients in a randomized, multicenter, double-blind study of the trivalent vaccine specifically developed to target and kill residual circulating cancer cells and micrometastases thought to cause recurrent sarcoma.  In the United States (US), there are approximately 13,200 sarcoma cases diagnosed each year, representing less than 1% of all new cancers.  Prognosis remains poor, with more than 5,200 patients in the US dying of the disease each year.  As in other malignancies, disease recurrence and metastasis are common in sarcoma.  Despite undergoing potentially curative surgical resection or combination t
'/>"/>

SOURCE MabVax Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute
2. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
3. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
4. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
5. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
6. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
7. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
10. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
11. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... --  Intrexon Corporation (NYSE: XON ) today ... after the market closes on May 11, 2015.  The ... 5:30 PM ET to discuss the results and provide ... may be accessed by dialing 1-888-346-3959 (Domestic US) and ... Call."  Participants may also access the live webcast through ...
(Date:5/1/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... it has priced an underwritten registered offering of 3,900,000 ... $9.00 per share, and granted the underwriters in the ... additional 585,000 shares of its common stock. The gross ... is expected to close on May 6, 2015, subject ...
(Date:5/1/2015)... -- Albany Molecular Research Inc. (NASDAQ: AMRI ) ... President and Chief Executive Officer, will present at the ... on Wednesday, May 13, 2015 at 4:20 p.m. ET. ... can be accessed at AMRI,s Investor Relations web site at ... be archived for 90 days following the live presentation. ...
(Date:4/30/2015)...   Tamir Biotechnology , a leading developer of ... Ebola antiviral therapy program. Clinical Progress ... being evaluated and considered by a number of clinicians ... the first quarter of 2015, the company participated in ... Evaluation of Potential Treatments and Vaccines For Ebola In ...
Breaking Biology Technology:Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4
... Oct. 2 454 Life Sciences, a Roche,company, ... to,conduct large scale genetic re-sequencing in hundreds of ... responses to a widely,prescribed class of drug. The ... sufficient genetic variation can be identified and,validated to ...
... SAFC(R), a member of the,Sigma-Aldrich(TM) Group ... plans to begin,construction of a new cGMP ... its Pharma sector,s St. Louis manufacturing campus.,This ... substance requirements,that demand a combination of small ...
... China, Oct. 2 HUYA Bioscience,International (HUYA), ... development of key disease-fighting drugs sourced from ... novel clinical stage anti-arrhythmic,compound from the prestigious ... of Sciences. The compound, HBI-3000 or ...
Cached Biology Technology:New Pharmacogenomic Approach: 454 Life Sciences and Perlegen to Collaborate in Drug Response Sequencing Study 2New Pharmacogenomic Approach: 454 Life Sciences and Perlegen to Collaborate in Drug Response Sequencing Study 3SAFC Supports Potent API Conjugate Manufacturing With New St. Louis Production Suite 2SAFC Supports Potent API Conjugate Manufacturing With New St. Louis Production Suite 3HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica 2HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica 3
(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
(Date:3/30/2015)... 26, 2015 Research and Markets ( ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... the Global Gesture Recognition market in Automotive Sector to ... 2013-2018. Gesture recognition is the ability of ... of an individual. Gesture recognition technology can be 2D-based ...
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... Science (via Science Express http://www.sciencexpress.org) on July 28th reveals ... in the open ocean ?the largest and least known ... climate change and fishing over the past 50 years, ... highlight a surprising global pattern of open ocean hotspots ...
... gene expression can influence the fates of cells ... than previously thought, according to new research from ... University of California, Berkeley. By combining experimental and ... found evidence that the virus may become latent ...
... has broken the immune system's code, report researchers from ... when its host is most vulnerable and to launch ... defenses. , In the 29 July 2005 issue of ... interferon-gamma, a chemical messenger the immune system uses to ...
Cached Biology News:Scientists discover global pattern of big fish diversity in open oceans 2Scientists discover global pattern of big fish diversity in open oceans 3Scientists discover global pattern of big fish diversity in open oceans 4Scientists discover global pattern of big fish diversity in open oceans 5Random gene expression may drive HIV into hiding 2Random gene expression may drive HIV into hiding 3Random gene expression may drive HIV into hiding 4Immune system's distress signal tells bacteria when to strike back 2Immune system's distress signal tells bacteria when to strike back 3